To include your compound in the COVID-19 Resource Center, submit it here.

Arbutus' ARB-1467 leads to HBsAg responses in Phase IIa for HBV infection

Arbutus Biopharma Corp. (NASDAQ:ABUS) reported data from 11 evaluable hepatitis B e antigen (HBeAg)-negative patients with chronic HBV infection in cohort 4 of the Phase IIa ARB-1467-002 trial showing that 0.4 mg/kg

Read the full 325 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE